Health and Healthcare
Invitrogen's Broader Stem Cell Monitor Kit (IVGN)
Published:
Invitrogen Corp. (NASDAQ:IVGN) has announced the launch of a new kit that allows researchers to quickly and reliably monitor the state of human embryonic stem cells. The STEMPRO® EZChek™ Multiplex PCR Kit allows scientists to monitor stem cells with one reaction, using fewer sample cells than ever before. The STEMPRO® EZChek™ Kit allows for the analysis of four early differentiation markers using a small sample and a single-tube reaction. Without the kit, researchers need to carry out five separate reactions in five tubes, using many more cells.
Invitrogen is already the leader or one of the leaders with more than $300 million per quarter in revenues in supplying tools and reagents for stem cell research with more than 1,200 products in the related market. This may be a much broader consolidated test solution, but with a portfolio that wide it may just be another day at the office.
The stock has not seen any noticeable trading pre-market. Its market cap as of Friday’s $83.90 close was $3.89 Billion, and the 52-week range is $54.70 to $84.14.
Jon C. Ogg
October 8, 2007
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.